




## SG UK Defensive Growth Plan 20 UK Four - Societe Generale

### Product Description

		Prices	Current Level
Underlying	FTSE100	Note Bid	N/A
Product Type	Enhanced Participation - Supertracker	Note Offer	N/A

### Overview

#### IPR Risk [Volatility]



#### Chance of Loss

#### Return (Annualised)

#### Chance of Gain

### General Information

#### Wrappers

ISA	Yes	Target Market	Security
Pension	Yes	Tax treatment	CGT
General Investment Account		Complexity	High
Offshore Bond			

## Simulated Investment Outlook

Simulated Outcome Probability

Average Payoff

**Risk & Returns**

**Issuer Risks**

Name	MULTI Aviva,Barclays,Lloyds,HSBC		
Ratings			
Ratings Agency	S&P	Moody's	Fitch
Rating	A-	B	A
Tier 1 Capital			16.2 %
Market Capitalisation (bn)			EUR 16.9
Chance of default over 12 months (Source: Bloomberg)			0.10 %

## Key Dates

Offer Close	05-May-2017
Strike Date	05-May-2017
Final Valuation Date	05-May-2023
Maturity Date	05-May-2023

## Details

Promoter	SocGen
Issuer	MULTI Aviva,Bardays,Lloyds,HSBC
Issuer Rating (S&P)	A-
ISIN	
Format	
Tax	CGT

## Identifying Codes

Cube Reference	#3657
ISIN	
Bloomberg	
Reuters	

## IPR Disclaimer

This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any investment offered by Investment Product Research Limited (IPR).

IPR uses historical information in order to provide an illustration of how certain parameters may have performed over a defined period. This presentation may also contain certain performance data based on back-testing, i.e., calculations of the hypothetical performance of a strategy, index or asset as if it had actually existed during a defined period of time. The scenarios, simulations, development expectations and forecasts contained in this presentation are for illustrative purposes only. Capitalised terms like ExpectedReturn are based on our stresstest methodology and are therefore not forecasts - they should only be used to assess a product's ranking versus the corresponding scores for the other products listed on our site.

IPR analysis is based on or derived from information generally available to the public from sources believed to be reliable. No representation or warranty can be given with respect to the accuracy or completeness of the information. We do not undertake to update this information.

IPR and its affiliates disclaim any and all liability relating to this information, including without limitation any express or implied representations or warranties for statements contained in, and omissions from, this information. Additional information is available on request.

IPR does not give investment, tax, accounting and legal or regulatory advice and investors should consult with their professional advisers.